Press Room

17 Mar 2017 2016 was another record year of biologics sales with antibodies accounting for two-thirds
25 Jan 2017 Oncolytic Viruses: a still undervalued technology with strong growth perspectives
19 Dec 2016 More than ever antibody-drug conjugates generated by new technologies are undergoing clinical proof-of-concept testing
09 Dec 2016 Complimentary copy of report „Blockbuster Biologics 2015: Sales of Recombinant Therapeutic Antibodies & Proteins“
10 Aug 2016 Beyond anti-CD19 CARTs: the future of CAR T-cells depends on the convergence of technologies
29 May 2016 Increasing impact of biosimilars on the market of originator therapeutic antibodies
13 May 2016 Improved next generation of T-cell redirecting bispecific antibodies enters clinical proof-of-concept phase
13 Mar 2016 Biologics sales in 2015 exceeded the USD 150 bln threshold
04 Feb 2016 RORgamma, a hot target for treatment of Th17 cell-mediated immune diseases, but also for immune therapy of cancer
02 Dec 2015 Antibody-drug conjugate technology on the path to productivity providing plenty of opportunities
18 Mar 2015 Innovation with therapeutic antibodies drives 2014 sales of recombinant biologics
12 Mar 2015 Engineered T-Cell Receptor and T-Cells: independent, but also complementary tools for immuno-oncology with great prospects
29 Dec 2014 Recombinant coagulation factors: market, products, R&D pipeline and new competition from alternative procoagulants and gene & cell therapy
16 Jul 2014 Botulinum Neurotoxins: opportunities for biosimilars and biosuperiors to capture market shares (2)
09 May 2014 Recombinant therapeutic antibodies consolidate as growth driver of biologics sales in 2013
23 Jan 2014 The exponential growth of the field of antibody-drug conjugates provides plenty of business opportunities
30 Jun 2013 Redistribution of market shares in the hemophilia market of recombinant coagulation factors due to new approvals and differential profiles
09 May 2013 Blockbuster Biologics 2012: sales are double that of 2006 driven by strong growth of recombinant antibodies
19 Mar 2012 The huge potential of GLP-1 receptor agonists in the diabetes market opens opportunities for technology providers and Big Pharma
24 Nov 2011 Blockbuster Drugs 2010: small molecules still dominating, but biologics strongly emerging
26 Oct 2011 Fierce Competition Requires Precision in Meeting the Needs of the Coagulation Factor Market
16 Sep 2011 Antibody-Drug Conjugates 2011 - real breakthrough still to come
07 Mar 2011 Biologics Sales in 2010 exceeded US$ 100 bln
08 Sep 2010 The Product Portfolio Strategy as Decisive Force in Forming the Future Coagulation Factor Market
14 Aug 2009 Changes ahead in the coagulation factor market by new entrants and technologies

La Merie Biologics

FREE Weekly News Bulletin

2016 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Top